Client Overview
The client is an Italian multinational pharmaceutical company with reporting obligations to the US FDA. The success story centers on support for the preparation and submission of the 2023 FDA CARES Act Report.
Background
The client needed an efficient and compliant process to prepare a time-bound FDA report. This required coordinated document handling, Regulatory review, and controlled submission execution to meet agency expectations without disrupting ongoing operations.
Services in Scope
Preparation support for the FDA CARES Act Report 2023.
Review and compilation of required submission content.
Submission support to the US FDA within required timelines.
Challenges
Need to compile and verify report content under reporting deadlines.
Requirement to maintain compliance while handling a specialized FDA reporting obligation.
Need for structured submission support to avoid delays or omissions.
Solution
Freyr supported the client with a reporting-focused Regulatory workflow covering content compilation, review, and submission execution. This helped the client manage a specialized FDA reporting requirement with greater control, timeliness, and compliance discipline.
1
Assessed the scope and reporting requirements for the FDA CARES Act Report 2023.
2
Compiled and reviewed the necessary content and supporting details for submission.
3
Structured the submission package to align with FDA reporting expectations.
4
Supported the timely submission of the completed report to the US FDA.
Impact
- Enabled timely submission of the FDA CARES Act Report 2023.
- Strengthened compliance handling for a specialized FDA reporting requirement.
- Reduced execution burden on the client’s internal teams through structured support.
Freyr’s support enabled the client to handle a complex FDA reporting requirement more efficiently and confidently. By streamlining compilation, review, and submission, the engagement ensured compliance and reduced operational complexity. This creates a repeatable model for future reporting.
